Millions more Americans could soon qualify for statins under new cholesterol guidelines
New ACC/AHA guidelines recommend statins for younger adults (as early as age 30) with LDL ?160 mg/dL, strong family history of heart disease, or high 30-year ASCVD risk. Lower LDL targets now set at <100 mg/dL (general), <70 mg/dL (high-risk), and <55 mg/dL (very high-risk).
The PREVENT-ASCVD calculator replaces older models but still faces criticism for overestimating risk and expanding statin markets. Conflicts of interest: Many guideline authors have financial ties to statin manufacturers (Pfizer, Merck), raising concerns about biased recommendations.
Proponents argue “lower LDL for longer” reduces plaque buildup, but skeptics warn of overprescription due to incidental findings (e.g., coronary calcium scans). Critics highlight statins’ side effects (muscle damage, diabetes risk) and question whether lifelong medication is truly preventive.
Guidelines prioritize drugs over lifestyle changes, despite evidence linking inflammation, metabolic health and toxins (not just LDL) to heart disease. Natural interventions (diet, detox, anti-inflammatory herbs) are sidelined, reinforcing Big Pharma’s profit-driven model.
Cases like Gigi Gari Campos (cardiac arrest at 34 due to delayed statin treatment) are used to justify early intervention, yet many doctors resist due to lack of clear consensus. Debate continues: Is this preventive care or a pathway to dependency? Millions more Americans may now be pushed onto statins without addressing systemic corruption in cardiology.
Read Full Article: https://www.naturalnews.com/2026-03-22-millions-eligible-for-statins-under-new-guidelines.html
